Chronic lymphocytic leukaemia: open trials in China

48 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT05091424
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Trial Treatment · Phase 1 · Hoffmann-La Roche
Peking University People's Hospital, Beijing · Southern Medical University Nanfang Hospital, Guangzhou · The First Affiliated Hospital of NanChang University, Nanchang · Tianjin Institute of Hematology & Blood Diseases Hospital, Tianjin
Registry updated 2026-11-05
NCT07218341
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Trial Treatment · Phase 4 · Eli Lilly and Company
Xuanwu Hospital, Capital Medical University, Beijing · Hunan Cancer Hospital, Changsha · Sun Yat-Sen University Cancer Center, Guangdong · Nanfang Hospital of Southern Medical University, Guangzhou · Gansu Provincial Cancer Hospital, Lanzhou · The First Affiliated Hospital of NanChang University, Nanchang · Fudan University Shanghai Cancer Center, Shanghai · Taizhou Hospital of Zhejiang Province, Taizhou · Tianjin Medical University Cancer Institute & Hospital, Tianjin · Hematology Hospital of the Chinese Academy of Medical Sciences, Tianjin · Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi · The Affiliated Hospital of Xuzhou Medical College, Xuzhou · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-11-04
NCT04016129
CAR-T Immunotherapy Targeting CD19- ALL
Trial Treatment · Phase 1/2 · Shenzhen Geno-Immune Medical Institute
Shenzhen Geno-immune Medical Institute, Shenzhen
Registry updated 2026-11-02
NCT04807881
Phase Ib Clinical Study of Keynatinib
Trial Treatment · Phase 1 · Medolution Ltd.
Peking University Third Hospital, Beijing · Cancer Hospital, Chinese Academy of Medical Sciences, Beijing · West China Hospital，Sichuan University, Chengdu · Fudan University Shanghai Cancer Center, Shanghai
Registry updated 2026-10-29
NCT06564038
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Trial Treatment · Phase 1/2 · AstraZeneca
Beijing · Guangzhou · Jinan · Tianjin · Zhengzhou
Registry updated 2026-10-28
NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
Peking University Third Hospital-Hematology (Site 2827), Beijing · The First Hospital of Jilin University-Hematology (Site 2803), Changchun · Hunan Cancer Hospital (Site 2822), Changsha · The Second Xiangya Hospital of Central South University (Site 2820), Changsha · West China Hospital Sichuan University (Site 2810), Chengdu · The Second Affiliated Hospital of Chongqing Medical University (Site 2825), Chongqing · Sun Yat-sen University Cancer Center-Internal Medicine (Site 2824), Guangzhou · The First Affiliated Hospital, Zhejiang University (Site 2826), Hangzhou · Anhui Provincial Hospital (Site 2808), Hefei · Liuzhou People's Hospital (Site 2817), Liuzhou · The First Affiliated Hospital of Nanchang University (Site 2815), Nanchang · Jiangsu Province Hospital (Site 2823), Nanjing · Guangxi Medical University Cancer Hospital (Site 2814), Nanning · Fudan University Shanghai Cancer Center (Site 2801), Shanghai · Huashan Hospital, Fudan University (Site 2821), Shanghai · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Unio (Site 2800), Tianjin · Wuhan Union Hospital (Site 2816), Wuhan · The Affiliated Hospital of Xuzhou Medical College (Site 2818), Xuzhou · Henan Cancer Hospital-hematology department (Site 2802), Zhengzhou
Registry updated 2026-10-27
NCT06697184
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Trial Treatment · Phase 1/2 · BeOne Medicines
Peking University Third Hospital, Beijing · Nanfang Hospital, Southern Medical University, Guangzhou · The First Affiliated Hospital of Soochow University, Suzhou
Registry updated 2026-10-26
NCT06943872
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Trial Treatment · Phase 3 · BeOne Medicines
China-Japan Friendship Hospital, Beijing · Xiangya Hospital of Central South University, Changsha · West China Hospital，Sichuan University, Chengdu · The First Affiliated Hospital of Chongqing Medical University, Chongqing · The First Affiliated Hospital of Fujian Medical University, Fuzhou · Fujian Medical University Union Hospitalqishan Branch, Fuzhou · Fujian Provincial Hospital, Fuzhou · Zhujiang Hospital of Southern Medical University, Guangzhou · Nanfang Hospital, Southern Medical University, Guangzhou · Guangzhou First Peoples Hospital, Guangzhou · Sir Run Run Shaw Hospital, Zhejiang University School of Medicinegrand Canal Branch, Hangzhou · Harbin Medical University Cancer Hospital, Harbin · The Affiliated Hospital of Inner Mongolia Medical University, Hohhot · Shandong Provincial Hospital, Jinan · Jining No1 Peoples Hospital West Branch, Jining · Jiangxi Cancer Hospital, Nanchang · Zhongda Hospital Southeast University, Nanjing · Guangxi Medical University Cancer Hospital Wuxiang Branch, Nanning · The Affiliated Peoples Hospital of Ningbo University, Ningbo · The Affiliated Hospital of Qingdao University Branch West Coast, Qingdao · Fudan University Shanghai Cancer Center, Shanghai · Affiliated Zhongshan Hospital of Fudan University, Shanghai · Liaoning Cancer Hospital and Institute, Shenyang · The First Hospital of China Medical University, Shenyang · The Second Hospital of Hebei Medical University, Shijiazhuang · Taihe Hospital, Shiyan · Suzhou Municipal Hospitalbaita Branch, Suzhou · Taizhou Hospital of Zhejiang Province (East), Taizhou · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch, Tianjin · Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Affiliated Hospital of Jiangnan University South Campus, Wuxi · The First Affiliated hospital of Xiamen University, Xiamen · Shaanxi Provincial Peoples Hospital, Xi'an · The First Affiliated Hospital of Xinxiang Medical University, Xinxiang · Northern Jiangsu Peoples hospital, Yangzhou
Registry updated 2026-10-23
NCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Trial Treatment · Phase 1/2 · BeOne Medicines
Beijing Chao-Yang Hospital, Capital Medical University, Beijing · Peking University Third Hospital, Beijing · The First Affiliated Hospital of Bengbu Medical University, Bengbu · The First Hospital of Jilin University, Changchun · The Second Xiangya Hospital of Central South University, Changsha · West China Hospital，Sichuan University, Chengdu · Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing · Affiliated Zhongshan Hospital of Dalian University, Dalian · Fujian Medical University Union Hospital, Fuzhou · Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou · Sun Yat-sen University Cancer Center, Guangzhou · The First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang, Hangzhou · Anhui Provincial Hospital, Hefei · Shandong Cancer Hospital, Jinan · First Affiliated Hospital of Kunming Medical University, Kunming · Jiangxi Province Cancer Hospital, Nanchang · The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang · Jiangsu Province Hospital, Nanjing · The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning · Nanyang Central Hospital, Nanyang · Qingdao Central Hospital, Qingdao · Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · The First Affiliated Hospital of Soochow University, Suzhou · Shanxi Provincial Cancer Hospital, Taiyuan · Institute of Hematology and Hospital of Blood Disease, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan · Xiangyang Central Hospital, Xiangyang · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-21
NCT07424833
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Trial Treatment · Phase 1 · Ascentage Pharma Group Inc.
Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-15
NCT07874451
Real-World Study of BCL-2 Inhibitor-Based Regimens in Chronic Lymphocytic Leukemia
Research · The First Affiliated Hospital with Nanjing Medical University
Jiangsu Province Hospital, Nanjing
Registry updated 2026-10-14
NCT06136559
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Peking University Third Hospital-Hematology (Site 2011), Beijing · Peking University First Hospital (Site 2022), Beijing · The First Hospital of Jilin University-Hematology (Site 2030), Changchun · Hunan Cancer Hospital (Site 2020), Changsha · The Second Xiangya Hospital of Central South University (Site 2010), Changsha · West China Hospital, Sichuan University-Head and Neck Oncology (Site 2026), Chengdu · Chongqing University Cancer Hospital (Site 2041), Chongqing · Southern Medical University Nanfang Hospital-Department of Hematopathology (Site 2006), Guangzhou · Sun Yat-sen University Cancer Center (Site 2028), Guangzhou · The Affiliated Hospital of Guizhou Medical University (Site 2024), Guiyang · Hainan General Hospital (Site 2018), Haikou · Zhejiang Cancer Hospital (Site 2017), Hangzhou · The first Affiliated Hospital, Zhejiang University School of Medicine-Hematology (Site 2002), Hangzhou · Anhui Provincial Cancer Hospital (Site 2001), Hefei · Shandong Cancer Hospital (Site 2003), Jinan · Liuzhou People's Hospital (Site 2029), Liuzhou · Jiangxi Provincial Cancer Hospital (Site 2009), Nanchang · The First Affiliated Hospital of Nanchang University (Site 2023), Nanchang · Jiangsu Province Hospital (Site 2000), Nanjing · Guangxi Medical University Affiliated Tumor Hospital (Site 2004), Nanning · The First Affliated Hospital of Suzhou University (Site 2027), Suzhou · Shanxi Cancer Hospital (Site 2033), Taiyuan · Tianjin Medical University Cancer Institute & Hospital-lymphoma (Site 2019), Tianjin · Institute of hematology&blood disease hospital-Lymphoma (Site 2005), Tianjin · Xinjiang Medical University Cancer Hospital - Urumqi (Site 2014), Ürümqi · Tongji Hospital Affiliated to Tongji Medical College of HUST (Site 2016), Wuhan · Union Hospital Tongji Medical College Huazhong University of Science and Technology (Site 2015), Wuhan · Shaanxi provincial people's hospital (Site 2012), Xi'an · The Affiliated Hospital of Xuzhou Medical College (Site 2013), Xuzhou · Henan Cancer Hospital-hematology department (Site 2025), Zhengzhou
Registry updated 2026-10-13
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Peking Union Medical College Hospital, Beijing · Nanfang Hospital, Southern Medical University, Guangzhou · Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Yichang Central Peoples Hospitaljiangnan Branch, Yichang · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-10-05
NCT06542250
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Trial Treatment · Phase 1/2 · AstraZeneca
Hangzhou · Shanghai
Registry updated 2026-09-30
NCT06973187
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Trial Treatment · Phase 3 · BeOne Medicines
Peking Union Medical College Hospital, Beijing · Binzhou Medical University Hospital, Binzhou · The First Hospital of Jilin University, Changchun · Hunan Cancer Hospital, Changsha · Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu · The Second Hospital of Dalian Medical University, Dalian · Dazhou Central Hospital, Dazhou · Fujian Medical University Union Hospital, Fuzhou · Sun Yat-sen University Cancer Center, Guangzhou · Guizhou Provincial Peoples Hospital, Guiyang · The First Affiliated Hospital of Harbin Medical University, Harbin · Jiangmen Central Hospital, Jiangmen · First Affiliated Hospital of Kunming Medical University, Kunming · The First Hospital of Lanzhou University, Lanzhou · The Affiliated Hospital of Southwest Medical University, Luzhou · The Second Affiliated Hospital of Nanchang University, Nanchang · The First Affiliated Hospital of Guangxi Medical University, Nanning · Affiliated Hospital of Nantong University, Nantong · The First Affiliated Hospital of Ningbo University, Ningbo · Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · Shengjing Hospital Of China Medical University, Shenyang · The Fourth Hospital of Hebei Medical University East Branch, Shijiazhuang · The First Affiliated Hospital of Soochow University, Suzhou · Taian City Central Hospital, Taian · Shanxi Bethune Hospital, Taiyuan · Institute of Hematology and Hospital of Blood Disease, Tianjin · The First Affiliated Hospital of Wenzhou Medical University, Wenzhou · Union Hospital, Tongji Medical College, Huazhong University of Science and Technologychegu Branch, Wuhan · Wuxi Peoples Hospital, Wuxi · The Second Affiliated Hospital of XiAn Jiaotong University, Xi'an · Qinghai university affiliated hospital, Xining · Xuchang Central Hospitalluminghu Branch, Xuchang · The affiliated hospital of xuzhou medical university, Xuzhou · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-09-28
NCT07277231
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Trial Treatment · Phase 3 · BeOne Medicines
Peking Union Medical College Hospital, Beijing · The Second Xiangya Hospital of Central South University, Changsha · Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu · The First Affiliated Hospital of Chongqing Medical University, Chongqing · The First Affiliated Hospital of Fujian Medical University, Fuzhou · Sun Yat Sen University Cancer Center Huangpu Branch, Guangzhou · Zhujiang Hospital of Southern Medical University, Guangzhou · Guizhou Provincial Peoples Hospital, Guiyang · The First Affiliated Hospital, Zhejiang University School of Medicinechengzhan, Hangzhou · Harbin Medical University Cancer Hospital, Harbin · Shandong Provincial Hospital, Jinan · First Affiliated Hospital of Kunming Medical University, Kunming · The Second Affiliated Hospital of Nanchang University, Nanchang · Jiangsu Province Hospital, Nanjing · The First Affiliated Hospital of Guangxi Medical University, Nanning · Affiliated Hospital of Nantong University, Nantong · Rui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai · Institute of Hematology and Hospital of Blood Disease, Tianjin · The Second Affiliated Hospital of XiAn Jiaotong University, Xi'an · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-09-28
NCT07831395
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
Trial Treatment · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China
The Second Xiangya Hospital of Central South University, Changsha · Nanfang Hospital, Southern Medical University, Guangzhou · The First Affiliated Hospital of NanChang University, Nanchang · Jiangsu Province Hospital, Nanjing · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-09-21
NCT06767891
Real-world Study of Acalabrutinib
Research · Ruijin Hospital
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2026-09-08
NCT04588922
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Trial Treatment · Phase 1/2 · Sellas Life Sciences Group
Affiliated Hospital of Hebei University, Baoding · The First Affiliated Hospital of Bengbu Medical College, Bengbu · Affiliated Cancer Hospital of Chongqing University, Chongqing · Cancer prevention and treatment center of Sun Yat sen University, Guangzhou · Guangdong Provincial People's Hospital, Guangzhou · The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou · Anhui Provincial Hospital, Hefei · LinYi Cancer Hospital, Linyi · The First Affiliated Hospital of NanChang University, Nanchang · Shengjing Hospital affiliated to China Medical University, Shenyang · The First Affiliated Hospital of Soochow University, Suzhou · Blood disease hospital, Chinese Academy of Medical Science, Tianjin · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-09-03
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Trial Treatment · Phase 3 · Loxo Oncology, Inc.
The Second Xiangya Hospital of Central South University, Changsha · Hunan Cancer Hospital, Changsha · Sun Yat-sen University Cancer Center, Guangzhou · Southern Medical University Nanfang Hospital, Guangzhou · Hainan General Hospital, Haikou · The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou · First Affiliated Hosp of College of Med, Zhejiang University, Hangzhou · Anhui Provincial Hospital, Hefei · The Second Hospital of Anhui Medical University, Hefei · Jiangxi Provincial Cancer Hospital, Nanchang · Guangxi Medical University Affiliated Tumor Hospital, Nanning · Fudan University Shanghai Cancer Center, Shanghai · Tianjin Medical University General Hospital, Tianjin · Blood Institute of the Chinese Academy of Medical science, Tianjin · Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Wu Han Tongji Hospital, Wuhan · The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu
Registry updated 2026-08-17
NCT07727083
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
Research · Rong Tao
Fudan University Shanghai Cancer Center, Shanghai
Registry updated 2026-08-13
NCT07763054
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Research · Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Hainan
Registry updated 2026-08-13
NCT07753369
A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Trial Treatment · Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Jiangsu Provincial People's Hospital, Nanjing · Henan Province, Zhengzhou
Registry updated 2026-08-11
NCT07609823
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Trial Treatment · Phase 2 · Guangzhou Lupeng Pharmaceutical Company LTD.
The First Affiliated Hospital of Nanjing Medical University, Nanjing
Registry updated 2026-07-30
NCT07609862
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Trial Treatment · Phase 1/2 · Guangzhou Lupeng Pharmaceutical Company LTD.
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Registry updated 2026-07-30

All Chronic lymphocytic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error